EICHORPublic-registry site landscape for NCT04197479, “A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients”, a Non-Alcoholic Fatty Liver Disease study sponsored by Madrigal Pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04197479 (registry record) |
| Study title | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients |
| Official title | A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1) |
| Sponsor | Madrigal Pharmaceuticals, Inc. |
| Condition(s) | Non-Alcoholic Fatty Liver Disease |
| Phase | PHASE3 |
| Listed sites | 77 |
| Intervention(s) | Placebo, Resmetirom |
| Site countries | United States, Puerto Rico |
Patient-friendly overview of this study: eichor.com/study/NCT04197479.
Eichor generates a preliminary site-risk snapshot for NCT04197479 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
